Clinical Trials Logo

Clinical Trial Summary

This is a controlled cohort study to assess the effect of improved sanitation on oral rotavirus vaccine performance in low-income urban neighbourhoods of Maputo, Mozambique. The specific hypotheses are that: (1) access to improved sanitation is associated with increased oral rotavirus vaccine immunogenicity; (2) enteric infection concurrent to oral rotavirus vaccination is associated with reduced oral rotavirus vaccine immunogenicity; and (3) Environmental Enteric Dysfunction is associated with reduced oral rotavirus vaccine immunogenicity. Pregnant women will be enrolled from the intervention and control arms of a previous sanitation trial (NCT02362932) post-intervention and will be enrolled at no later than eight months' gestation and then followed to 4 months of age of the infant. Blood samples and faeces will be taken from the infant at the time of administration of the first dose of the oral rotavirus vaccine and four weeks after the second dose of the vaccine. The primary outcome of interest in the study is oral rotavirus vaccine immunogenicity among participating vaccinated infants. Seroconversion is defined as a ≥ fourfold rise in serum anti-rotavirus IgA titers between first dose of oral RV vaccine and 4 weeks (+/- 1 week) after second dose of oral RV vaccine. Enteric infections are defined as the presence of ≥ 1 of the following enteric infections in stool: adenovirus 40/41, rotavirus A, norovirus GI/GII, Salmonella spp. (including serovars Typhi and Paratyphi), Campylobacter spp. (C. jejuni, C. coli, C. lari), Shigella spp. (S. boydii, S. sonnei, S. flexneri, S. dysenteriae), Clostridium difficile Toxin A/B, enterotoxigenic Escherichia coli (ETEC) LT/ST, E. coli O157, Shiga-like toxin-producing E. coli (STEC) stx1/stx2, Yersinia enterocolitica, Vibrio cholerae, Giardia lamblia, Entamoeba histolytica, and Cryptosporidium spp. (C. parvum, C. hominis). Environmental Enteric Dysfunction is measured via a combined disease activity score including faecal markers of intestinal inflammation and permeability: neopterin, α-1 antitrypsin, and myeloperoxidase in stool.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03313128
Study type Observational
Source London School of Hygiene and Tropical Medicine
Contact Oliver D Cumming, MSc
Phone +442076368636
Email oliver.cumming@lshtm.ac.uk
Status Recruiting
Phase
Start date October 1, 2017
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Completed NCT02538211 - The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses N/A
Completed NCT02220439 - Does the Fecal Microbiome Influence Rotarix Immunogenicity N/A
Withdrawn NCT00757926 - Safety and Immunogenicity Study of the Recombinant Human Bovine Reassortant Rotavirus Vaccine in Healthy Indian Infants Phase 1/Phase 2
Not yet recruiting NCT00484952 - Surveillance of Hospitalizations Due to Rotavirus Infections Among Children From Israel N/A
Completed NCT00092443 - Dose Confirmation Efficacy Study (V260-007) Phase 3
Terminated NCT01357174 - ROTATEQ™ Post-Marketing Surveillance in the Philippines N/A
Recruiting NCT01363726 - Surveillance of Rotavirus Gastroenteritis in Children <5 Years N/A
Completed NCT00130832 - Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED) Phase 3
Recruiting NCT06080906 - Phase II Clinical Trial of the Inactivated Rotavirus Vaccine Phase 2
Completed NCT02542462 - Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study Phase 4
Completed NCT00346892 - To Evaluate 2 Doses of GSK Biologicals' Oral Live Attenuated Human HRV Vaccine Co-administered With Either OPV or IPV Phase 2
Not yet recruiting NCT05212935 - A Surveillance Study on Timing and Coverage Of Rotavirus and MenB Vaccine Co-administration in Campania Region, Italy
Completed NCT00092456 - Consistency Lots Vaccine Study (V260-009) Phase 3
Completed NCT00981669 - Rotavirus Vaccine Produced by Butantan Institute Phase 1
Completed NCT05037435 - Safety and Immunological Efficacy of the Pentavalent Rotavirus Vaccine - Rota-V-Aid™ (Live Attenuated Oral, Freeze-dried) at Healthy Adults Aged 18 to 45 Years. Phase 3
Completed NCT03483116 - A Phase II Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine Phase 2
Completed NCT03870061 - Evaluation of an Infant Immunization Encouragement Program in Nigeria N/A
Active, not recruiting NCT05621655 - Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers Phase 2
Completed NCT00280111 - Safety and Immunogenicity Study of Live Attenuated Indian Rotavirus Vaccine Candidate Strains 116E and I321 in Infants Phase 1
Completed NCT00090233 - Rotavirus Efficacy and Safety Trial (REST)(V260-006) Phase 3